Eurocine Vaccines presented at BOS Virtual 2021
On 1 July 2021, CEO Hans Arwidsson gave a presentation at BOS, Biotech Outsourcing Strategies, Virtual 2021, which is an event arranged by Bio2Business Ltd., London. The event, which took place between 29 June and 1 July, brought together stakeholders in pharmaceutical outsourcing to share experiences and develop new business relationships.
The presentation, where CEO Hans Arwidsson described the development of a chlamydia vaccine, had the title "Build a fruitful relationship in BioTech - A case of how to create a successful outsourcing partnership between a vaccine developer and a CDMO, Eurocine Vaccines, and Biovian", and was held together with Magnus Gustafsson, Biovian.
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
+46 70 634 0171
Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.
Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.
The company is in the possession of its own technology platform, Endocine™, which has been tested in four extensive clinical studies with over 400 subjects.
Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden and has attracted several internationally merited vaccine specialists to its board.